首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1736708

2026 年至 2032 年血球容積比檢測設備市場（依產品、應用、最終用戶及地區）

Hematocrit Test Devices Market By Product, Application, End-User, & Region for 2026-2032

出版日期: 2025年05月07日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血球比容檢測設備市場評估-2026-2032

自動分析儀和攜帶式照護現場工具等技術的發展將透過提供更快、更準確、更便利的檢測來推動市場成長。因此，技術進步將倍增市場規模的成長，到2024年將達到43.6億美元，到2032年將達到57.8億美元。

醫療保健支出的不斷成長，推動了對診斷工具的更多投資，加速了技術創新和血球比容檢測設備的普及。因此，由於醫療保健支出的不斷成長，預計2026年至2032年期間該市場的複合年成長率將達到3.60%。

血球比容檢測設備市場定義/概述

血球比容測試儀器是診斷醫學中必不可少的工具，用於測量紅血球 (RBC) 在人體總血容量中的百分比。此測量值稱為血球比容值，它能夠為各種健康狀況提供寶貴的見解，從發燒等輕微疾病到貧血和癌症等嚴重，不一而足。血球比容測試計算的是紅血球體積與總血容量的比率。偏離正常範圍通常表示存在影響紅血球生成或壽命的疾病。

進行血球容積比檢測需要採集少量血液樣本，通常透過指尖採血或靜脈穿刺。然後將樣本放入特製試管中，放入離心機中旋轉，離心機根據血液成分的密度進行分離，使紅血球沉澱到試管底部。自動化分析儀和照護現場血球容積比檢測設備推動了這個檢測過程，使其更快、更準確、更方便。這些設備擴大與數位技術融合，使檢測更加高效可靠。血球容積比檢測設備在早期診斷和監測中發揮關鍵作用，幫助醫護人員管理各種健康狀況並改善患者預後。

血球容積比測試需求的不斷成長如何推動血球容積比測試設備市場的成長？

貧血、紅血球增多症和其他血液疾病的病例正在增加，對血球比容測試的需求也隨之增加，以便早期診斷和有效的疾病管理。 WHO（2022）報告稱，非傳染性疾病每年導致 4,100 萬人死亡，佔全球整體的 74%。 CDC（2021）指出，1.33 億美國人患有至少一種慢性病。根據 NIH（2022）的數據，自 2020 年以來，全球糖尿病盛行率增加了 8.5%。不斷成長的老齡人口容易患貧血和各種血液疾病，定期進行血細胞比容測試對於監測健康和預防併發症至關重要。隨著老齡人口的成長，預計對這些測試和設備的需求將會增加。根據聯合國世界人口展望，2022 年 65 歲以上人口到 2050 年將達到 16 億。 WHO 估計，80% 的老年人口患有至少一種慢性疾病。歐盟報告稱，2020年至2022年間，老年人照護方面的醫療支出將增加15%。

美國紅十字會（2022年）報告稱，美國每天需要約29,000個紅血球。世界衛生組織報告稱，全球捐血需求將增加6%。急診室的輸血程序將增加18%。

血球比容檢測設備（包括自動分析儀和攜帶式照護現場設備）的進步透過提供更快、更準確和更便捷的檢測解決方案，推動了市場成長。自動化和數位技術的整合進一步提高了檢測效率和可靠性，使這些設備在醫療保健領域的價值日益提升。與 2020 年相比，2022 年 FDA核准的照護現場設備將增加 28%。美國國立衛生研究院 (NIH) 報告稱，2020 年至 2023 年 POC 檢測市場的複合年成長率為 12.3%。 2020 年至 2022 年，POC 檢測的健保報銷將增加 34%。世界反興奮劑機構 (2022)：運動員血液檢測將增加 15%。奧林匹克委員會 (2021) 對 85% 的耐力運動實施強制性血球比容監測。根據運動醫學會的數據，到 2022 年，運動醫學市場將達到 72 億美元。

高昂的檢測成本將如何阻礙血球容積比檢測設備市場的成長？

血球比容檢測以及其他診斷程序的成本可能很高，尤其是在開發中國家。這限制了那些無法負擔檢測費用的人獲得檢測的機會，凸顯了對更實惠的診斷方案的需求，以擴大檢測管道。根據美國國立衛生研究院 (NIH) (2022) 的數據，從 2020 年到 2022 年，醫療設備研發成本增加了 32%。 FDA 報告稱，2022 年新型診斷設備的平均開發成本達到 3,100 萬美元。醫療技術協會 (2021) 指出，45% 的小型醫療設備公司將高昂的研發成本視為成長的主要障礙。

許多地區，特別是開發中國家，無法充分獲得醫療設施、診斷實驗室和血庫。這限制了血球容積比檢測服務的普及，尤其是在農村和服務欠缺地區。世界衛生組織（2022 年）報告稱，全球 47% 的人口無法獲得基本的診斷服務。世界銀行報告稱，低收入國家只有 38% 的醫療機構擁有基本的診斷設備。聯合國兒童基金會（2023 年）指出，32 億人無法獲得體外診斷檢測。農村和服務欠缺地區有限的醫療基礎設施阻礙了血球比容檢測的普及。為了應對這項挑戰並支持更廣泛地進行檢測，擴大醫療基礎設施和改善診斷服務覆蓋率的議程至關重要。

The development of advanced devices, including automated analyzers and portable point-of-care tools, enhances market growth by offering faster, more accurate, and convenient testing. Thus, the technological advancements surge the growth of market size surpassing USD 4.36 Billion in 2024 to reach the valuation of USD 5.78 Billion by 2032.

Rising healthcare expenditure supports greater investment in diagnostic tools, accelerating the innovation and adoption of hematocrit test devices. Thus, the increasing healthcare expenditure enables the market to grow at a CAGR of 3.60% from 2026 to 2032.

Hematocrit Test Devices Market: Definition/ Overview

Hematocrit test devices are essential tools in diagnostic medicine, used to measure the proportion of red blood cells (RBCs) in a person's total blood volume. This measurement, known as hematocrit, provides valuable insights into various health conditions, from mild ailments like fever to more serious diseases such as anemia or cancer. A hematocrit test calculates the ratio of RBC volume to total blood volume, with deviations from normal ranges often indicating conditions that affect red blood cell production or lifespan.

To perform a hematocrit test, a small blood sample is collected, usually through a finger prick or venipuncture. The sample is then placed in a specialized tube and spun in a centrifuge, which separates the blood components by density, allowing the red blood cells to settle at the bottom of the tube. Automated analyzers and point-of-care hematocrit test devices have advanced this process, making it faster, more accurate, and more convenient. These devices are increasingly integrated with digital technologies, improving the efficiency and reliability of testing. Hematocrit test devices play a crucial role in early diagnosis and monitoring, supporting healthcare providers in managing various health conditions and enhancing patient outcomes.

How the Increasing Demand for Hematocrit Testing Surge the Growth of Hematocrit Test Devices Market?

Growing cases of anemia, polycythemia, and other blood disorders are increasing the demand for hematocrit testing for early diagnosis and effective disease management. WHO (2022) reported that non-communicable diseases cause 41 million deaths each year, equivalent to 74% of all deaths globally. CDC (2021) stated that 133 million Americans have at least one chronic disease. According to NIH (2022), diabetes prevalence increased by 8.5% globally since 2020. The increasing geriatric population is more prone to anemia and various blood disorders, making regular hematocrit testing essential for monitoring health and preventing complications. With a growing elderly population, the demand for these tests and devices is expected to rise. UN World Population Prospects 2022 people aged 65+ will reach 1.6 billion by 2050. WHO estimated that 80% of older adults have at least one chronic condition. The European Union reported a 15% increase in healthcare spending for elderly care from 2020-2022.

American Red Cross (2022) nearly 29,000 units of red blood cells are needed daily in the U.S. WHO reported a 6% increase in blood donation demands globally. Blood transfusion procedures increased by 18% in emergency departments.

Advancements in hematocrit test devices, including automated analyzers and portable point-of-care units, are driving market growth by offering faster, more accurate, and convenient testing solutions. The integration of automation and digital technologies further enhances testing efficiency and reliability, making these devices increasingly valuable in healthcare. FDA approved 28% more point-of-care devices in 2022 compared to 2020. NIH reported that the POC testing market grew at 12.3% CAGR from 2020-2023. Medicare claims for POC testing increased by 34% between 2020-2022. World Anti-Doping Agency (2022): 15% increase in blood testing among athletes. The Olympic Committee (2021) implemented mandatory hematocrit monitoring for 85% of endurance sports. According to the Sports Medicine Association, the sports medicine market will reach $7.2 billion by 2022.

How does the High Testing Cost Impede the Growth of the Hematocrit Testing Device Market?

Hematocrit testing, along with other diagnostic procedures, can be costly, especially in developing countries. This limits access to testing for individuals with limited financial resources, highlighting the need for more affordable diagnostic options to broaden access. According to NIH (2022), medical device R&D costs increased by 32% from 2020-2022. FDA reported that the average development cost for new diagnostic devices reached USD 31 Million in 2022. Medical Technology Association (2021) noted that 45% of small device companies cited high R&D costs as their primary growth barrier

In many regions, particularly in developing countries, access to healthcare facilities, diagnostic laboratories, and blood banks is insufficient. This restricts the availability of hematocrit testing services, especially in rural and underserved areas. WHO (2022) reported that 47% of the global population lacks access to essential diagnostic services. World Bank only 38% of healthcare facilities in low-income countries have basic diagnostic equipment. UNICEF (2023) stated that 3.2 billion people lack access to in-vitro diagnostic testing. Limited healthcare infrastructure in rural and underserved areas hinders the accessibility of hematocrit testing. Efforts to expand healthcare infrastructure and improve diagnostic service access are essential to address this challenge and support broader testing availability.

Category-Wise Acumens

How the Compact and Portable Design Surge the Growth of Hematocrit Test Meter Segment?

The hematocrit test meter segment dominates the Hematocrit Test Devices Market, owing to its compact and portable design that makes it well-suited for point-of-care testing across diverse healthcare settings, including primary care, clinics, and home healthcare. These meters are user-friendly, highly transportable, and cost-effective, offering a practical solution for settings where access to larger, stationary equipment is limited. Their rapid result delivery enables healthcare providers to diagnose and treat conditions promptly, which is especially beneficial in urgent care scenarios.

To address the rising demand for point-of-care testing, manufacturers are prioritizing the development of smaller and even more portable hematocrit test meters, enhancing their usability in various environments. Additionally, the integration of these devices with digital health platforms facilitates remote monitoring and data analysis, allowing healthcare professionals to track patients' hematocrit levels and overall health remotely. Ongoing advancements in automation are further improving the functionality of hematocrit test meters, increasing their testing throughput and accuracy. This combination of portability, digital integration, and automation makes hematocrit test meters a key growth driver in the Hematocrit Test Devices Market, as they support efficient, accessible, and reliable diagnostics.

How does the Deficiency of Red Blood Cells and Monitoring for Effective Treatment Foster the Growth of the Anemia Segment?

The anemia segment is dominant in the Hematocrit Test Devices Market owing to the critical role of hematocrit testing in diagnosing and managing anemia. Anemia, characterized by a deficiency of red blood cells or hemoglobin, is a widespread condition requiring timely detection and ongoing monitoring for effective treatment. Hematocrit tests enable early identification of anemia, which is essential for initiating prompt treatment to prevent further health complications.

Monitoring hematocrit levels also allows healthcare providers to track the effectiveness of anemia treatments over time, ensuring that treatment plans are achieving the desired outcomes. Beyond anemia, hematocrit testing is expanding into applications like assessing hydration status, evaluating kidney function, and identifying nutritional deficiencies, broadening the utility of these devices. Additionally, the shift toward personalized medicine has further strengthened demand in the anemia segment. Hematocrit tests can support tailored treatment plans by offering insight into an individual's unique health needs, enabling clinicians to adjust treatments accordingly.

Country/Region-wise Acumens

How the Advanced Healthcare Infrastructure & High Healthcare Spending Hematocrit Test Devices Market in North America?

North America substantially dominates the Hematocrit Test Devices Market driven by the region's benefits from a robust healthcare infrastructure, featuring advanced diagnostic facilities and a highly skilled healthcare workforce. U.S. healthcare spending reached USD 4.3 Trillion in 2021. American Hospital Association (2022) reported 6,093 hospitals with advanced diagnostic facilities. Healthcare spending per capita in the U.S. increased by 9.7% from 2020-2022.

The increasing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and kidney disorders drives the need for regular blood tests, including hematocrit testing, to support effective management and treatment. CDC (2022) reported that 6 in 10 U.S. adults have a chronic disease, with 4 in 10 having multiple conditions. American Cancer Society (2021) estimated 1.9 million new cancer cases, require regular blood monitoring. NIH (2023) data showed that anemia affects approximately 5.6% of the U.S. population, with higher rates in the elderly and women.

FDA approved 37% more hematology devices in 2022 compared to 2020. The U.S. medical device industry invested $22.4 billion in R&D. Clinical trials for hematology devices increased by 28% between 2020-2023.

How Economic Growth and Increasing Healthcare Investment Surge the Growth of Hematocrit Test Devices Market in Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the Hematocrit Test Devices Market during the forecast period owing to the rapid economic growth in countries like China, India, and South Korea is leading to increased healthcare spending and improved healthcare infrastructure. China's healthcare spending grew by 12.8% to reach USD 1.1 Trillion in 2022 (National Bureau of Statistics of China). India increased its healthcare budget by 137% between 2020-2023. Southeast Asian healthcare infrastructure investments reached USD 28.5 Billion in 2022.

The increasing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and anemia is driving the demand for diagnostic tools like hematocrit test devices. WHO Western Pacific Region (2022) reported 1.9 billion people with 35% above the age of 50. China CDC (2021) documented 116 million diabetes cases requiring regular blood monitoring. Indian Council of Medical Research (2022) reported a 38% increase in blood disorder cases. Thailand welcomed 3.5 million medical tourists in 2022. Singapore's medical tourism revenue grew by 15% annually from 2020-2022. South Korea reported a 25% increase in international patients for medical procedures.

Competitive Landscape

The Hematocrit Test Devices Market is characterized by a mix of established global players and emerging regional companies. Key players in this market are continuously innovating to develop advanced devices and expand their market reach.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Hematocrit Test Devices Market include Sysmex Corporation, Abbott Laboratories, Hoffmann-La Roche Ltd., Siemens AG, Beckman Coulter, Nihon Kohden Corporation, Boule Diagnostics AB, EKF Diagnostics, Nova Biomedical, HORIBA, Ltd.

Latest Developments

In March 2024, Siemens Healthineers announced the launch of its next-generation automated hematology analyzer, with integrated hematocrit testing capabilities that promise 30% faster findings.

In April 2020, Nova Biomedical announced the launch of the State EMS Basic blood testing system for ambulance and emergency care in CE mark countries.

1 INTRODUCTION OF GLOBAL HEMATOCRIT TEST DEVICES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HEMATOCRIT TEST DEVICES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY PRODUCT

5.1 Overview
5.2 Hematocrit Test Meter
5.3 Hematocrit Test Analyzer
5.4 Reagents and Consumables

6 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY APPLICATION

6.1 Overview
6.2 Anemia
6.3 Polycythemia Vera
6.4 Congenital Heart Diseases
6.5 Others

7 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY END-USER

7.1 Overview
7.2 Hospitals & clinics
7.3 Diagnostic Centers
7.4 Others

8 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL HEMATOCRIT TEST DEVICES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Sysmex Corporation
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Abbott Laboratories
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 F. Hoffmann-La Roche Ltd.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Siemens AG
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Beckman Coulter
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Nihon Kohden Corporation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Boule Diagnosis AB
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 EKF Diagnostics
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Nova Biomedical
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 HORIBA Ltd.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments